Compare BRFH & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRFH | FEMY |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 22.4M |
| IPO Year | 2010 | 2021 |
| Metric | BRFH | FEMY |
|---|---|---|
| Price | $1.13 | $2.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $5.50 |
| AVG Volume (30 Days) | 24.6K | ★ 173.5K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.53 | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | $211,467.00 | ★ $2,293,313.00 |
| Revenue This Year | $115.22 | $105.16 |
| Revenue Next Year | $16.91 | $200.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 92.09 | 40.77 |
| 52 Week Low | $1.09 | $0.29 |
| 52 Week High | $4.25 | $6.29 |
| Indicator | BRFH | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 29.87 | 42.01 |
| Support Level | N/A | $0.41 |
| Resistance Level | $1.45 | $3.33 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 5.56 | 10.10 |
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.